CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Read more about CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes.
VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis. Read more about VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.
Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. Read more about Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.
5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Read more about 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Read more about American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.
Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Read more about Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
Macrophage activation syndrome-like manifestations (MAS-L) following BCMA-directed CAR T-cells in multiple myeloma Read more about Macrophage activation syndrome-like manifestations (MAS-L) following BCMA-directed CAR T-cells in multiple myeloma
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Read more about IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.
Infectious complications in relapsed refractory multiple myeloma patients after BCMA CAR T therapy Read more about Infectious complications in relapsed refractory multiple myeloma patients after BCMA CAR T therapy
FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Read more about FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma.
